إعلان
إعلان
SPRO
Spero Therapeutics, Inc. Common Stock
2.35
USDبرعاية
+0.02
+0.69%
٠٢ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
2.38
+0.03
+1.24%
تقارير أرباح SPRO
النسبة الإيجابية المفاجئة
SPRO تفوق 21 من 33 آخر التقديرات.
64%
التقرير التالي
بيانات التقرير القادم
٢٥ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.20
التغير الضمني من Q3 25 (Revenue/ EPS)
-100.00%
/+53.85%
التغير الضمني من Q4 24 (Revenue/ EPS)
-100.00%
/-47.37%
Spero Therapeutics, Inc. Common Stock earnings per share and revenue
On ١٣ نوفمبر ٢٠٢٥, SPRO reported earnings of -0.13 USD per share (EPS) for Q3 25, beating the estimate of -0.25 USD, resulting in a 49.02% surprise. Revenue reached 5.44 مليون, compared to an expected --, with a 0.00% difference. The market reacted with a -1.23% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.20 USD, with revenue projected to reach -- USD, implying an increase of 53.85% EPS, and decrease of -100.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
٢٢ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.57
الفعلي
-$0.73
مفاجئة
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
١٩ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.25
الفعلي
-$0.19
مفاجئة
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
What were Spero Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Spero Therapeutics, Inc. Common Stock reported EPS of -$0.13, beating estimates by 49.02%, and revenue of $5.44M, 0% as expectations.
How did the market react to Spero Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -1.23%, changed from $2.44 before the earnings release to $2.41 the day after.
When is Spero Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ٢٥ مارس ٢٠٢٦.
What are the forecasts for Spero Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Spero Therapeutics, Inc. Common Stock is expected to report EPS of -$0.20 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان